Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Technology evaluation: pegaptanib, Eyetech/Pfizer.

Stanley A Vinores1

  • 1Johns Hopkins Hospital, Wilmer Ophthalmological Institute, 825 Maumenee, 600 N Wolfe Street, Baltimore, MD 21287-9289, USA. svinores@jhmi.edu

Current Opinion in Molecular Therapeutics
|February 6, 2004
PubMed
Summary

Pegaptanib, an anti-VEGF aptamer, is being developed to treat eye conditions like macular degeneration. This angiogenesis inhibitor shows potential for various ocular diseases.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

VEGF receptor blockade markedly reduces retinal microglia/macrophage infiltration into laser-induced CNV.

PloS one·2013
Same author

Reduced retinal neovascularization, vascular permeability, and apoptosis in ischemic retinopathy in the absence of prolyl hydroxylase-1 due to the prevention of hyperoxia-induced vascular obliteration.

Investigative ophthalmology & visual science·2011
Same author

High glucose-induced altered basement membrane composition and structure increases trans-endothelial permeability: implications for diabetic retinopathy.

Current eye research·2011
Same author

Blockade of VEGFR1 and 2 suppresses pathological angiogenesis and vascular leakage in the eye.

PloS one·2011
Same author

Placenta growth factor-1 exerts time-dependent stabilization of adherens junctions following VEGF-induced vascular permeability.

PloS one·2011
Same author

Vascular endothelial growth factor-B gene transfer exacerbates retinal and choroidal neovascularization and vasopermeability without promoting inflammation.

Molecular vision·2011

Area of Science:

  • Ophthalmology
  • Pharmacology
  • Oncology

Background:

  • Pegaptanib is an anti-vascular endothelial growth factor (anti-VEGF) aptamer developed as an angiogenesis inhibitor.
  • Eyetech Pharmaceuticals and Pfizer are co-developing pegaptanib for ocular diseases.

Purpose of the Study:

  • To evaluate pegaptanib as a potential treatment for age-related macular degeneration and diabetic macular edema.
  • To explore other potential ocular disease applications for pegaptanib.
  • To note previous investigation of pegaptanib for cancer treatment by Gilead, with no recent data.

Main Methods:

  • Drug co-development and investigation.
  • Clinical evaluation for specific ocular indications.

Main Results:

  • Pegaptanib is under development for age-related macular degeneration and diabetic macular edema.
  • Potential for treating other ocular diseases exists.
  • Gilead's prior cancer investigation yielded no published data since 1999.

Conclusions:

  • Pegaptanib demonstrates promise as an angiogenesis inhibitor for treating major ocular diseases.
  • Ongoing development focuses on ophthalmology, with past research in oncology noted.

Related Experiment Videos